AP BIOSCIENCES INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.2 TWD | 0.00% |
|
+0.33% | +29.18% |
| 03-19 | AP Biosciences Inc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 32.25 1.04K 44.08 | Capitalization | 3.02B 97.37B 4.12B |
|---|---|---|---|---|---|
| Net income 2022 | -289M -9.33B -395M | Net income 2023 | -339M -10.94B -463M | EV / Sales 2022 * | - |
| Net cash position 2022 | 1.08B 34.81B 1.47B | Net cash position 2023 | 658M 21.23B 899M | EV / Sales 2023 | 73,150,237 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
-8.89
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.27% |
More Fundamentals
* Assessed data
| 1 week | +0.33% | ||
| Current month | -0.99% | ||
| 1 month | +3.26% | ||
| 3 months | -11.21% | ||
| 6 months | +17.81% | ||
| Current year | +29.18% |
1 week
59.30
60.50
1 month
56.1061.90
Current year
45.0070.00
1 year
41.0584.20
3 years
41.0584.20
5 years
41.0584.20
10 years
41.0584.20
| Managers | Title | Age | Since |
|---|---|---|---|
Jeng-Horng Her
FOU | Founder | - | 13-05-26 |
Shu Cheng Lin
DFI | Director of Finance/CFO | - | 22-10-17 |
Wan Ju Tseng
ADM | Chief Administrative Officer | - | 22-10-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chih Chuan Chen
CHM | Chairman | - | 23-05-22 |
Jeng-Horng Her
FOU | Founder | - | 13-05-26 |
Shih Ming Lin
BRD | Director/Board Member | - | 23-05-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 60.2 | 0.00% | 34,276 |
| 24-05-20 | 60.2 | +0.84% | 30,258 |
| 24-05-17 | 59.7 | -0.17% | 60,423 |
| 24-05-16 | 59.8 | -0.33% | 32,076 |
| 24-05-15 | 60 | 0.00% | 30,526 |
End-of-day quote Taipei Exchange, May 20, 2024
More quotes
AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.
| 1st Jan change | Capi. | |
|---|---|---|
| +29.18% | 121M | |
| +8.63% | 114B | |
| +13.17% | 107B | |
| -12.76% | 22.22B | |
| -2.53% | 21.28B | |
| -7.19% | 17.51B | |
| -39.93% | 17.17B | |
| +6.67% | 14.14B | |
| +33.90% | 12.2B | |
| -28.60% | 7.83B |
- Stock Market
- Equities
- 6945 Stock